Lakefront Biotherapeutics (LKFT) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Perrigo (PRGO) over the past year, losing 14.1% versus a loss of 32.9%. Over five years, LKFT leads with a -43.9% price change compared with -67.5% for PRGO. Perrigo is the larger company by market cap ($2.01 billion vs $1.96 billion), about 1.0 times the size.
Perrigo pays a dividend yielding 7.97%, while Lakefront Biotherapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | PRGO |
|---|---|---|
| Share price | $30.00 | $14.55 |
| Market cap | $1.96B | $2.01B |
| 1-day change | +2.32% | +3.93% |
| YTD return | -8.26% | +4.53% |
| 1-year return | -14.11% | -32.89% |
| 5-year return | -43.95% | -67.46% |
| P/E ratio (TTM) | 2.85 | — |
| Forward P/E | — | 6.07 |
| EPS (TTM) | $10.52 | $-12.28 |
| Dividend yield | 0.00% | 7.97% |
| Annual dividend | $0.00 | $1.16 |
| 52-week high | $36.24 | $22.02 |
| 52-week low | $25.68 | $9.23 |
| Distance from 52-week high | -17.22% | -33.92% |
| Analyst consensus | hold | none |
| Avg. price target upside | +0.60% | +13.40% |
| Average volume | 265.76K | 2.81M |
| Shares outstanding | 65.48M | 138.37M |
| Employees | 196 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed PRGO by 18.8 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.97% vs 0.00%).
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
LKFT vs PRGO FAQ
Which is bigger, Lakefront Biotherapeutics or Perrigo?
Perrigo (PRGO) is larger, with a market capitalization of $2.01B compared with $1.96B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or PRGO?
LKFT returned -14.11% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Lakefront Biotherapeutics or Perrigo?
Perrigo pays a dividend yielding 7.97%, while Lakefront Biotherapeutics does not currently pay a regular dividend.
Are Lakefront Biotherapeutics and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.